Introduction
Animal health and human health are closely linked because of the existence of a large number of zoonotic diseases and the impact of unhealthy livestock on human food. The World Organisation for Animal Health (OIE) has therefore helped to develop the 'One Health' concept and focused its strategic policy on the need to ensure animal health and welfare worldwide.
Veterinary medicinal products are considered essential to ensuring animal health and welfare and to improving public health in general. Livestock producers and animal health professionals in the field need fast access to good quality, safe and effective veterinary medicinal products at a reasonable price. This is crucial to ensuring the health of livestock and hence to limiting epizootics. This, in turn, helps to prevent the transmission of diseases such as zoonoses to humans through contact with animals or their environment, through a vector or by consuming food of animal origin.
While this applies to all countries, it is of particular importance in developing countries, which all too often have neither sufficient resources nor the conditions for securing a supply of effective veterinary medicinal products.
This makes it essential for national authorities to create the necessary conditions, in particular by implementing a strict and clearly defined policy for veterinary medicinal products. Protecting animal health and human food security, by ensuring a healthier herd, will also contribute to economic development and poverty reduction.
Antimicrobials are vital drugs because they are key in treating and controlling infectious diseases in both humans and animals. However, the use of antimicrobials (to treat humans, animals and plants) has led to the development of resistance, which is of increasing concern, mainly because no new antimicrobial molecules are being discovered.
Antimicrobial resistance is a global phenomenon that respects no species barriers and has become a leading animal health concern in the same way as certain zoonotic diseases.
Public policy on veterinary medicinal products is therefore an ongoing concern for the OIE and is a fully-fledged component of animal health policies. As the more specific problem of antimicrobial resistance has become a threat to human and animal health, the OIE has also defined international recommendations for preventing the spread of resistance. The OIE' s general strategy, described in its Fifth Strategic Plan for 2011-2015, addresses this concern.
General strategy of the OIE, a major international player Over the past 20 years, the main topics of international debate have been: surveillance of antimicrobial consumption and resistance in veterinary medicine, risk analysis and the prudent use of antimicrobials. 
Guidelines on surveillance and monitoring
Harmonisation of national antimicrobial resistance surveillance and monitoring programmes (Chapter 6.7. of the Terrestrial Code) Regular surveillance of antimicrobial resistance, and its development in pathogenic and non-pathogenic bacteria found in animals, food of animal origin or the environment, constitutes a critical part of any strategy aimed at limiting the spread of antimicrobial resistance. Resistance surveillance is also used to optimise the choice of antimicrobials for treating animals and to make recommendations to veterinary prescribers. Accordingly, in May 2003, the OIE adopted guidelines on the harmonisation of national antimicrobial resistance surveillance and monitoring programmes in animals and in food of animal origin intended for human consumption (5) . The main objective of these guidelines is to provide criteria for developing national antimicrobial resistance surveillance and monitoring programmes or for harmonising existing ones.
Such surveillance is used to follow trends in antimicrobial resistance in bacteria, detect the emergence of new antimicrobial resistance mechanisms and provide the data necessary for conducting risk analyses with relevance for human and animal health. These data then inform the recommendations made to prescribers for prudent antimicrobial use. While the goal of the Oslo meeting was to draw up these lists in order to implement preventive measures, the conclusions of the Rome meeting were very different. The Rome meeting recommended that the WHO and OIE lists of critically important antimicrobial agents should be considered when prioritising drug/animal species/pathogen combinations for risk assessment.
Methodologies for setting riskassessment priorities were proposed for this purpose and the meeting called for the emphasis to be placed on cephalosporins, fluoroquinolones and macrolides, in particular for Salmonella spp., Campylobacter spp. and Escherichia coli.
Country capacity building
Most of the international meetings recommended building the capacity of countries to control antimicrobial resistance.
The OIE has led discussions in this area and set up a programme to evaluate the capacity of Veterinary Services. A resolution to this effect was adopted in May 2009, providing for measures to be introduced in the field of veterinary medicinal products, in particular antimicrobial resistance. A number of international conferences and training courses have been held or are planned.
In 2008, the WHO set up the AGISAR Advisory Group to implement specific projects on antimicrobial resistance arising from the use of antimicrobials in food animals.
OIE Fifth Strategic Plan
In response to this comprehensive global approach, the OIE has enshrined in its 2010 Fifth Strategic Plan a strong commitment to strengthen collaboration with FAO Monitoring of the quantities of antimicrobials used in animal husbandry (Chapter 6.8. of the Terrestrial Code)
The main purpose of these guidelines is to define the approach to be used for collecting objective and quantitative information to evaluate antimicrobial usage patterns in animal production, by animal species and antimicrobial class (6), in order to evaluate antimicrobial exposure.
The information provided in these guidelines can be helpful in interpreting antimicrobial resistance surveillance data and in responding to resistance problems in a more precise and targeted way by implementing mitigation strategies tailored to the situations encountered. The information may also assist in evaluating the effectiveness of any measures adopted.
The basic data collected should be the annual weight in kilograms of the active ingredient of the antimicrobial(s) used for each species, together with the type of use and route of administration. Information on dose rates and duration of treatment is important in estimating the use of antimicrobials in animals.
Guidelines on legislation, use of veterinary medicinal products and risk analysis

Guidelines on veterinary legislation
Veterinary legislation is a crucial element of the national infrastructure that enables Veterinary Services to carry out their key functions efficiently in all fields of animal health, including surveillance and rapid response to, and prevention and control of, animal health emergencies. Veterinary medicinal products are therefore a vital component of veterinary legislation implementation.
At its 79th General Session in May 2011, the OIE adopted guidelines setting out recommendations for developing a regulatory framework to enable Members to introduce an effective animal health policy and endow control services with the necessary legal powers. These guidelines serve to support countries in improving the health of their livestock and complying with OIE standards (10).
Apart from making recommendations on the general legal framework, the powers of the competent authority and potential systems of penalties, these guidelines make specific recommendations regarding the minimum legislation to be introduced in each technical sector. A chapter devoted to veterinary medicine defines the main areas to be regulated throughout the veterinary medicinal product chain, ranging from marketing authorisation, to raw materials, manufacturing and distribution conditions and quality control of veterinary products.
Risk assessment for antimicrobial resistance arising from the use of antimicrobials in animals (Chapter 6.10. of the Terrestrial Code)
These guidelines set out a methodology enabling OIE Member Countries to establish a risk analysis for antimicrobial resistance in order to assess and manage the human and animal health risks of resistance arising from antimicrobial use in animals (8) .
This risk analysis must include:
-hazard identification based on the results of surveillance -a release assessment of resistant microorganisms or resistance determinants -an exposure assessment of probable exposure to identified hazards -a consequence assessment of the potential consequences of a given exposure.
All this is designed to estimate the risk and help to determine the management and risk communication measures to be undertaken.
Responsible and prudent use of antimicrobial agents in veterinary medicine (Chapter 6.9. of the Terrestrial Code) Chapter 6.9. of the Terrestrial Code makes recommendations directed at all stakeholders in the veterinary medicinal product chain to ensure their prudent use of antimicrobials (7).
The recommendations are intended primarily for the competent authorities in charge of establishing the regulatory framework required for assessing and authorising antimicrobials, controlling their quality and advertising and supervising their distribution and surveillance.
Recommendations are also aimed at the pharmaceutical industry, retail distributors of veterinary antimicrobial products, prescribing veterinarians and food-animal producers.
Special attention must therefore be paid to each stage of the use of antimicrobials, extending from their authorisation to their administration to animals, with specific recommendations for each stakeholder at every stage in an antimicrobial' s life.
Prospects and future work
The OIE is currently developing guidelines on resistance to antimicrobial agents used in aquaculture. The aim is to adapt the guidelines for terrestrial animals to take into account the specific characteristics of the aquaculture industry. Preliminary guidelines on the responsible and prudent use of antimicrobials in aquaculture were adopted at the 79th OIE General Session for inclusion in the Aquatic Code (Chapter 6.3.) (9) .
An ad hoc group was set up to revise the current guidelines on antimicrobial resistance in the Terrestrial Code, which were drawn up in 2004 and 2005. A first draft was submitted to OIE Members for comment. The revision of Chapter 6.10. on risk assessment for antimicrobial resistance will take into account the results of work by the Codex Task Force (1).
OIE tools
The OIE provides its Member Countries with a number of tools to help them to implement the antimicrobial resistance guidelines more effectively. General OIE tools include the Tool for the Evaluation of Performance of Veterinary Services (OIE PVS Tool), which enables countries to make an accurate diagnosis of their ability to manage risk, assess their degree of implementation of OIE guidelines and identify areas for improvement. The OIE has also introduced more specific tools for veterinary medicinal products by designating Collaborating Centres for veterinary medicinal products, establishing networks of national focal points and organising training seminars.
OIE PVS Pathway
The OIE PVS Pathway is a global programme for the sustainable improvement of the compliance of a country' s Veterinary Services with OIE standards on the quality of Veterinary Services (11).
To support this objective, there is a crucial need for appropriate legislation in the animal health and welfare field and its strict implementation through appropriate human and financial resources.
The OIE international standards and guidelines form the basis for independent external country evaluations of the quality of Veterinary Services and animal health systems. A specific methodology has been developed and the OIE has published the OIE PVS Tool as the basis for evaluating performance against the international standards published in the Terrestrial Code.
Only OIE-certified PVS experts can carry out independent external PVS Evaluations of country Veterinary Services and PVS Gap Analysis. They have undergone training sessions organised by the OIE (funded by donors to the OIE World Animal Health and Welfare Fund). All experts use standard tools, indicators and experts' manuals (including template reports) prepared and published by OIE Headquarters.
Between 2006 and 2010, the OIE progressively developed the OIE PVS Pathway. The first steps in the pathway are the country PVS Evaluation (carried out using the OIE PVS Tool) and the PVS Gap Analysis mission. Each step is integrated into a comprehensive, staged approach that provides targeted support for the systematic strengthening of Veterinary Services based on international standards. 
PVS Gap Analysis
The PVS Gap Analysis Tool (a 'prescription tool') is a quantitative evaluation of a country' s needs and priorities (based on the outcome of the independent external evaluation of the country' s Veterinary Services using the OIE PVS Tool). A series of different national factors and conditions needs to be taken into consideration when shifting from the qualitative evaluation (country PVS report) to a quantitative assessment of needs and priorities (PVS Gap Analysis report).
A PVS Gap Analysis mission facilitates the definition of the objectives of a country' s Veterinary Services in terms of compliance with OIE international standards on quality of Veterinary Services. Each objective must be suitably adapted to national constraints and priorities. The country PVS Gap Analysis report includes an indicative annual budget and, where relevant, an exceptional budget (for exceptional investments); these two budgets are consolidated to propose an indicative five-year budget for the Veterinary Services.
Veterinary legislation
The ability to prepare and implement legislation are among the 46 critical competencies identified in the OIE PVS Tool.
The OIE is aware that in many developing countries veterinary legislation is outdated and inadequate for addressing current and future challenges. At the request of Members, the OIE has developed guidelines on veterinary legislation, setting out the essential elements that should be covered by legislation to meet OIE quality standards. Any country that has undergone a PVS evaluation can request a follow-up mission to obtain advice and assistance in modernising their national veterinary legislation. These guidelines will be used to update legislation in the light of the gaps identified by the OIE PVS evaluation and must of course be tailored to each country' s specific situation.
OIE global programmes for modernising veterinary legislation
As a follow-up to a PVS evaluation, and at the request of Members, the OIE conducts missions to help governments wishing to modernise their national veterinary legislation and thereby help Veterinary Services to meet OIE standards. After an initial 'identification' mission the country may request longer-term collaboration with the OIE, under a formal agreement, with the objective of modernising the national veterinary legislation.
Veterinary legislation missions, like the other components of the PVS Pathway, are carried out by experts trained and certified by the OIE. The first OIE global conference on veterinary legislation, entitled 'Modernising veterinary legislation for good governance', took place in Djerba, Tunisia, in December 2010.
Tools specific to veterinary medicinal products
Collaborating Centres for veterinary medicinal products
The OIE relies on special structures -Collaborating Centres -to provide specific expertise in a given specialty 
Network of national focal points and capacity-building activities
Regional programmes for building the capacity of Veterinary Services in OIE Member Countries are established annually. They promote networking between country Delegates to the OIE and national focal points.
The OIE has asked each of its Members to appoint national focal points for certain issues it considers important, including veterinary medicinal products. At its 76th General Session, the OIE reaffirmed the important role of national focal points and adopted terms of reference defining their roles and responsibilities. The permanent Delegate is the official representative of his or her Member Country in dealings with the OIE, while national focal points are specialists in the respective subject and responsible for providing expertise to the permanent Delegate, as well as acting as a key contact person for the OIE in connection with opinions or questionnaires on the subject in question.
The OIE Regional and Sub-Regional Representations organised two seminars on veterinary medicinal products: one for the Africa region, held in Dakar in 2008, and the other for the Middle East, held in Syria in 2009. The aim of these regional seminars was to develop capacity and provide Delegates and national focal points with information and in-service training on veterinary medicinal products. They were also intended to allow national focal points to get acquainted and engage in networking.
The regional seminars have now been replaced by training courses for national focal points. The first cycle of training was held in each of the five regions from July 2010 to May 2011. A second cycle began in September 2011 and is planned to conclude in 2012.
Conclusion
Antimicrobial resistance and the use of antimicrobial agents in veterinary medicine are complex issues that are currently a source of major international concern. This concern should be taken into account and an appropriate response provided, supported by tangible results.
The main unanswered question is: how much responsibility does veterinary antimicrobial use bear for the emergence, selection and spread of resistant bacteria with the potential to infect humans? Most international reports on the subject conclude that, while antimicrobial use in humans is primarily responsible for the emergence of bacterial resistance, veterinary use of antimicrobials is also partly responsible.
It is therefore crucial that the OIE engages with this issue, while also continuing to address the problem of zoonotic diseases. That is why the OIE has included objectives for veterinary medicinal products, especially antimicrobials, in its Strategic Plan.
Consequently, the OIE plays an active part in discussions on this subject in conjunction with other international organisations such as FAO and WHO. Furthermore, the OIE has adopted guidelines both for defining harmonised methodologies for antimicrobial resistance surveillance and monitoring and for helping countries to conduct a risk analysis tailored to their situation and to take appropriate management measures.
Antimicrobial resistance is a global phenomenon that affects all countries. Clearly not all developing countries have a sufficiently developed legal system to provide a regulatory framework for veterinary medicinal products, including antimicrobials, from design to use. It is also essential for competent authorities to be endowed with competent inspection services and quality control structures in order to detect counterfeit drugs. The OIE has therefore developed recommendations and tools to help countries to improve their legislation. It has included this issue in its programme of assistance to countries by offering them structural enhancement tools -OIE PVS Tool, PVS Gap Analysis, veterinary legislation support, and training for veterinary national focal points -with the aid of the OIE network of three Collaborating Centres for veterinary medicinal products.
Only by mobilising all countries to improve the quality of antimicrobials, to introduce antimicrobial resistance surveillance and to implement measures for the responsible and prudent use of antimicrobials, will it be possible to halt the spread of antimicrobial resistance.
